TIVDAK
(Tisotumab Vedotin)Phase 2Antibody–drug conjugate
PfizerTIVDAK is one of 74 small molecule programs targeting Vulvar Carcinoma. It is currently in Phase 2.
3
Indications
12
Total Trials
4
Active Trials
73
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Votrient
NovartisPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Perjeta
RochePhase 3
Bavencio
EMD SeronoPhase 3
Liposomal Doxorubicin
Eli LillyPhase 3
Veliparib
AbbViePhase 3
Trastuzumab Deruxtecan
AstraZenecaPhase 3
Chiauranib
CChipscreen Biosciences, Ltd.
Phase 3
AK104
AAkeso
Phase 3
In Vitro Sensitivity-Directed Chemotherapy
CChildren's Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Patients With Solid Tumors4 trials
Cervical Cancer4 trials
Solid Malignancies1 trial
Advanced Solid Malignancies1 trial
Regulatory
FDA Approval Timeline[4]
Sep 20, 2021
TIVDAK
BLA BLA761208
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tisotumab Vedotin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]